This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klauber-DeMore, N. Articles by Gerald, W. L. Search for Related Content PubMed PubMed Citation Articles by Klauber-DeMore, N. Articles by Gerald, W. L.

Biological Behavior of Human Breast Cancer Micrometastases¹

Departments of Surgery [N. K-D., K. J. V. Z., P. I. B.] and Pathology [I. L., W. G.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Purpose: Clinically undetectable micrometastases may account for disease recurrence in breast cancer patients after variable disease-free intervals. However, little is known about the cellular mechanisms controlling human breast cancer micrometastases. We compared tumor proliferation rate, apoptotic index, and angiogenesis in human breast cancer micrometastases with those of macroscopic axillary lymph node metastases.

Experimental Design: Seven breast cancer micrometastases (<2 mm) obtained from the sentinel nodes of seven patients were compared with 13 macrometastases (lymph node replaced with tumor) obtained from 13 patients. The tissue was fixed in formalin, embedded in paraffin, serially sectioned, and evaluated by H&E and immunohistochemistry for cytokeratin. Tumor proliferation rate was assessed as the number of Ki-67-positive nuclei/total number of tumor nuclei. Tumor vascularity was quantified using antibody to factor VIII to identify microvessels per high-power field (at x400). Apoptosis was quantified using the terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling method. Results were analyzed with the Wilcoxon rank-sum test.

Results: Median size of micrometastases was 0.5 mm (range, 0.4–1.0), and the median number of tumor nuclei/section was 143 (range, 90–312). Median proliferation rate for macrometastases was greater than for micrometastases (35% versus 12%; P = 0.003). Median microvessel density/high-power field for macrometastases was greater than for micrometastases (17 versus 1; P < 0.001). There was no difference in apoptotic index between macrometastases and micrometastases (1.1% versus 0.7%; P = not significant).

Conclusions: Human breast cancer micrometastases have lower tumor proliferation rates and angiogenesis than breast cancer macrometastases. These characteristics may explain their differential growth patterns.

This article has been cited by other articles:

				C. Teixeira Soares, U. Frederigue-Junior, and L. A. de Luca Anatomopathological Analysis of Sentinel and Nonsentinel Lymph Nodes in Breast Cancer: Hematoxylin-Eosin Versus Immunohistochemistry International Journal of Surgical Pathology, October 1, 2007; 15(4): 358 - 368. [Abstract] [PDF]

				N. Klauber-DeMore, D. W. Ollila, D. T. Moore, C. Livasy, B. F. Calvo, H. J. Kim, E. C. Dees, C. I. Sartor, L. R. Sawyer, M. Graham II, et al. Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic Ann. Surg. Oncol., May 1, 2006; 13(5): 685 - 691. [Abstract] [Full Text] [PDF]

				E. N. Stathopoulos, E. Sanidas, M. Kafousi, D. Mavroudis, J. Askoxylakis, V. Bozionelou, M. Perraki, D. Tsiftsis, and V. Georgoulias Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes Ann. Onc., February 1, 2005; 16(2): 240 - 246. [Abstract] [Full Text] [PDF]